Hives

The FDA has accepted the resubmission of the supplemental biologics license application for Dupixent to treat chronic spontaneous urticaria in adults and children, Regeneron Pharmaceutical and Sanofi announced in a press release.

BOSTON — Patients with chronic inducible urticaria saw improvements in itch and wheals with barzolvolimab in 12 weeks, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Patients with chronic spontaneous urticaria experienced significant improvements through 24 weeks with dupilumab, according to an abstract presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

BOSTON — Chronic spontaneous urticaria symptoms improved with 1 week of remibrutinib treatment, according to a poster presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

Sirolimus may be a safe and effective alternative for patients with chronic spontaneous urticaria who do not respond to other treatments, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with chronic spontaneous urticaria experienced early symptom improvements that were sustained through 52 weeks with remibrutinib, according to a presentation at the European Academy of Allergy & Clinical Immunology Congress.

LOUISVILLE, Ky. — Dupilumab improved chronic spontaneous urticaria among patients whose disease did not respond to H1 antihistamines, according to a presentation here.

Researchers identified an association between a self-reported history of high-risk allergy and an increased risk for allergic reactions after receipt of an mRNA COVID-19 vaccine.

The FDA has approved a self-injectable formulation of Xolair for appropriate patients with moderate to severe persistent allergic asthma, nasal polyps or chronic idiopathic urticaria, according to the manufacturers.